Arsanis is developing novel therapeutics to prevent and treat bacterial infections associated with antibiotic resistance and/or high mortality. This is a pioneering field and has experienced failures so far, therefore considered to be associated with high risk. The FFG grants greatly support us to perform a more extensive target validation and selection to develop the most optimal product candidates and increase our likelihood of success.
Eszter Nagy, MD PhD
Dr. Nagy has 15 year long experience in discovery and pre-clinical development of novel vaccines, adjuvants and anti-infective monoclonal antibodies. In 2010, she co-founded Arsanis, Inc with Tillman Gerngross (Adimab LLC, USA) and serves as the president and Chief Scientific Officer of the company, as well as the managing director of the wholly owned Austrian subsidiary, Arsanis Biosciences GmbH. Arsanis is dedicated to the development of antibody based therapeutics to fight severe infectious diseases. Between 1999 and 2010, Dr. Nagy worked at Intercell where she made fundamental contributions to the technology platforms developed for the identification of bacterial antigens and novel adjuvant/delivery systems and served as Senior Vice President of Research. Previously, Dr. Nagy worked in academic research for 10 years in the fields of molecular biology, cellular immunology and cellular physiology at several institutions in the US (Dartmouth College and Medical School, Hanover, NH; Roswell Park Cancer Institute, Buffalo, NY) and Hungary (Medical University, Pecs, Hungary). She has published > 50 research papers in the fields of anti-microbial immunity, bacterial pathogenesis and antigen discovery for vaccine development and named as inventor on ~ 30 patents in these fields.